This inventor holds 3 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 2 EPO patents. Top assignee: Medimmune Limited. Active years: 2017-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2017-2022
Title: Innovations in Obesity Treatment by Inventor Nicole Burmeister
Introduction
Nicole Burmeister is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of metabolic disease treatment, particularly focusing on obesity. With a total of 3 patents to her name, Burmeister is recognized for her innovative approaches in this critical area of healthcare.
Latest Patents
Among her latest patents, Burmeister has developed glucagon/GLP-1 agonists for the treatment of obesity. This disclosure provides GLP-1/glucagon agonist peptides aimed at treating metabolic diseases, such as obesity. Her work in this domain showcases her commitment to advancing medical science and improving patient outcomes.
Career Highlights
Nicole Burmeister is currently associated with MedImmune Limited, where she continues to push the boundaries of research and innovation. Her role at the company allows her to collaborate with other experts in the field and contribute to groundbreaking developments in obesity treatment.
Collaborations
Some of her notable coworkers include Balaji Agoram and Madeleine Antonsson. Their collective expertise enhances the research environment at MedImmune Limited, fostering innovation and collaboration.
Conclusion
Nicole Burmeister's work in developing glucagon/GLP-1 agonists represents a significant advancement in the treatment of obesity. Her contributions to the field are invaluable, and her ongoing research promises to lead to further innovations in metabolic disease management.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile